Vol 28, No 4 (2022)
Research paper
Published online: 2022-12-30
Leukotrienes in the atherosclerotic cardiovascular diseases — a systematic review
1
, 2, 23, 4, 3, 13, 3, 13
, 2, 23, 4, 3, 13, 3, 13
DOI: 10.5603/AA.2022.0013
Acta Angiologica 2022;28(4):147-153.
Abstract
Introduction: The role of inflammation in the pathogenesis of atherosclerotic diseases is strongly suggested.
There are multiple studies indicating the possibility of a pathophysiological connection between atherosclerotic
changes and leukotrienes (LTs) — the products of arachidonic acid metabolism. The goal of this systematic
review, performed in line with the PRISMA statement, was to investigate the potential role of LTs in the pathophysiology
of atherosclerotic cardiovascular diseases (CVD).
Material and methods: The MEDLINE, EMBASE, and Cochrane Database of Systematic Reviews were
searched to identify the potentially eligible studies. Publications that contained information on any type of LTs
identified in blood or urine were included in the review. A database search identified 2082 records. Reliable LTs
identification in patients with CVD was used in 30 publications.
Results: Stable and acute forms of coronary artery disease are characterized by the overproduction of different
types of LTs. The level of LTB4 and LTC4 in the blood is elevated in patients with cerebral ischemia. Patients with
acute and chronic peripheral artery disease have elevated levels of LTE4 in urine.
Conclusions: The findings of this systematic review show that there is a clear tendency to indicate the association
of cardiovascular atherosclerotic diseases with increased production of LTs. This dependency detailed
characteristic remains unclear and the question on the impact of elevated leukotrienes on clinical atherosclerotic
disease manifestations is still open.
Keywords: atherosclerosiscoronary artery diseaseleukotrienesreview
References
- Barquera S, Pedroza-Tobías A, Medina C, et al. Global Overview of the Epidemiology of Atherosclerotic Cardiovascular Disease. Arch Med Res. 2015; 46(5): 328–338.
- Bäck M, Yurdagul A, Tabas I, et al. Inflammation and its resolution in atherosclerosis: mediators and therapeutic opportunities. Nat Rev Cardiol. 2019; 16(7): 389–406.
- Jawien J, Korbut R. The current view on the role of leukotrienes in atherogenesis. J Physiol Pharmacol an Off J Polish Physiol Soc. 2010 Dec. ; 61(6): 647–50.
- Maga P, Sanak M, Jawien J, et al. 11-dehydro thromboxane B2 levels after percutaneous transluminal angioplasty in patients with peripheral arterial occlusive disease during a one year follow-up period. J Physiol Pharmacol. 2016; 67(3): 377–383.
- Szczeklik A, Sladek K, Dworski R, et al. Bronchial aspirin challenge causes specific eicosanoid response in aspirin-sensitive asthmatics. Am J Respir Crit Care Med. 1996; 154(6 Pt 1): 1608–1614.
- Murphy RC, Gijón MA. Biosynthesis and metabolism of leukotrienes. Biochem J. 2007; 405(3): 379–395.
- Takase B, Maruyama T, Kurita A, et al. Arachidonic acid metabolites in acute myocardial infarction. Angiology. 1996; 47(7): 649–661.
- Mayatepek E, Hoffmann G. Leukotrienes: Biosynthesis, Metabolism, and Pathophysiologic Significance. Pediatric Research. 1995; 37(1): 1–9.
- Sirois P. Leukotrienes: One step in our understanding of asthma. Respir Investig. 2019; 57(2): 97–110.
- Peters-Golden M. Expanding roles for leukotrienes in airway inflammation. Curr Allergy Asthma Rep. 2008; 8(4): 367–373.
- Riccioni G, Bäck M, Capra V. Leukotrienes and atherosclerosis. Curr Drug Targets. 2010; 11(7): 882–887.
- Moher D, Liberati A, Tetzlaff J, et al. PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009; 151(4): 264–9, W64.
- Moola S, Munn Z, Tufanaru C, Aromataris E, Sears K, Sfetcu R, Currie M, Qureshi R, Mattis P, Lisy K MP-F. Systematic reviews of etiology and risk. In: Aromataris E MZ, editor. Joanna Briggs Institute Reviewer’s Manual. The Joanna Briggs Institute; 2017.
- Gautier-Veyret E, Bäck M, Arnaud C, et al. Cysteinyl-leukotriene pathway as a new therapeutic target for the treatment of atherosclerosis related to obstructive sleep apnea syndrome. Pharmacol Res. 2018; 134: 311–319.
- Allen SP, Sampson AP, Piper PJ, et al. Enhanced excretion of urinary leukotriene E4 in coronary artery disease and after coronary artery bypass surgery. Coron Artery Dis. 1993; 4(10): 899–904.
- Maga P, Sanak M, Rewerska B, et al. Urinary cysteinyl leukotrienes in one-year follow-up of percutaneous transluminal angioplasty for peripheral arterial occlusive disease. Atherosclerosis. 2016; 249: 174–180.
- Rossi P, Kuukasjärvi P, Salenius JP, et al. Leukotriene production is increased in lower limb ischemia. International Journal of Angiology. 2011; 6(02): 89–90.
- Brezinski DA, Nesto RW, Serhan CN. Angioplasty triggers intracoronary leukotrienes and lipoxin A4. Impact of aspirin therapy. Circulation. 1992; 86(1): 56–63.
- He G, Ye S, Hui J, et al. Interrelationships between ALOX5AP polymorphisms, serum leukotriene B4 level and risk of acute coronary syndrome. PLoS One. 2014; 9(9): e106596.
- Gómez-Hernández A, Sánchez-Galán E, Ortego M, et al. Effect of intensive atorvastatin therapy on prostaglandin E2 levels and metalloproteinase-9 activity in the plasma of patients with non-ST-elevation acute coronary syndrome. Am J Cardiol. 2008 Jul. ; 102(1): 12–8.
- Sai Li, YanQiu Z, DongMei C, et al. Effect of rosuvastatin and benazepril on matrix metalloproteinase-2, matrix metalloproteinase-9 and leukotriene B4 of patients with acute myocardial infarction. Trop J Pharm Res. 2021; 18(3): 625–630.
- John F, Kavitha S, Panicker S, et al. Elevated levels of leukotriene B4 and thromboxane B2 distinguish chest pain of cardiac and non cardiac origin. Indian Heart J. 2013; 65(3): 295–299.
- Guo-Ping He, Shan Ye, Jing-Jiao H, et al. INTERRELATION AMONG THE SERUM LEUKOTRIENE B4 LEVEL, ARACHIDONATE 5-LIPOXYGENASE ACTIVATING PROTEIN GENE SG13S89G/A POLYMORPHISM AND RISK OF ACUTE MYOCARDIAL INFARCTION. Heart. 2012; 98(Suppl 2): E190.1–E190.
- Xu S, Tang L, Mi Y, et al. Clinical significance of leukotriene b4 and extracellular matrix metalloproteinase inducer in acute coronary syndrome. Clin Invest Med. 2013; 36(6): E282–E289.
- Carry M, Korley V, Willerson JT, et al. Increased urinary leukotriene excretion in patients with cardiac ischemia. In vivo evidence for 5-lipoxygenase activation. Circulation. 1992; 85(1): 230–236.
- Stodółkiewicz E, Rewerska B, Rzeszutko M et al. Leukotriene biosynthesis in coronary artery disease. Polish Arch Intern Med [Internet]. 2018;128(1):934–42. Available from: http://www.embase.com/search/results?subaction=viewrecord%7B%5C&%7Dfrom=export%7B%5C&%7Did=L620523169. .
- Stodółkiewicz E. Staged revascularization following initial urgent PCI is associated with elevated leukotrienes and thromboxane levels in patients with acute myocardial infarction and multivessel disease. Kardiol Pol [Internet]. 2013;71:96–7. Available from: http://www.embase.com/search/results?
- Ibrahim I, Shawky A, Mansour Y, Rashed K, Bahnasy W EE. Leukotriene B4 as an early predictor of carotid atherosclerosis in patients with obstructive sleep apnea. Eur Respir J [Internet]. 2014;44. Available from: http://www.embase.com/search/results?subaction=viewrecord&from=export&id=L71849635.
- Aktan S, Aykut C, Ercan S. Leukotriene C4 and prostaglandin E2 activities in the serum and cerebrospinal fluid during acute cerebral ischemia. Prostaglandins Leukot Essent Fatty Acids. 1991; 43(4): 247–249.
- Wang G, Wang Y, Sun H, et al. Variants of the arachidonate 5-lipoxygenase-activating protein (ALOX5AP) gene and risk of ischemic stroke in Han Chinese of eastern China. J Biomed Res. 2011; 25(5): 319–327.
- Katsura K, Minamisawa H, Katayama Y, et al. Plasma levels of leukotriene C4, B4 slow reacting substance of anaphylaxis in chloronological phases of cerebrovascular disease. Prostaglandins. 1988; 36(5): 655–665.
- Chan SuJ, Ng MPE, Zhao H, et al. Early and Sustained Increases in Leukotriene B Levels Are Associated with Poor Clinical Outcome in Ischemic Stroke Patients. Neurotherapeutics. 2020; 17(1): 282–293.
- Ingelsson E, Yin Li, Bäck M. Nationwide cohort study of the leukotriene receptor antagonist montelukast and incident or recurrent cardiovascular disease. J Allergy Clin Immunol. 2012; 129(3): 702–707.e2.
- Guo-Ping He, Shan Ye, Guo-Ping He. ASSOCIATIONS OF THE SERUM LEUKOTRIENE B4 LEVEL WITH ARACHIDONATE 5-LIPOXYGENASE ACTIVATING PROTEIN GENE POLYMORPHISMS AND THE RISK OF ACUTE CORONARY SYNDROME. Heart. 2012; 98(Suppl 2): E195.2–E195.
- Guo-Ping He, Shan Ye, Jing-Jiao H, et al. RELATIONSHIP OF ARACHIDONATE 5-LIPOXYGENASE ACTIVATING PROTEIN GENE SG13S114T/A POLYMORPHISM WITH THE SERUM LEUKOTRIENE B4 LEVEL IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION. Heart. 2012; 98(Suppl 2): E187.1–E187.
- Guo-Ping He, Shan Ye, Jing-Jiao H, et al. RELATIONSHIP OF THE SERUM LEUKOTRIENE B4 LEVEL WITH THE RISK OF UNSTABLE ANGINA PECTORIS AND THE ARACHIDONATE 5-LIPOXYGENASE ACTIVATING PROTEIN GENE SG13S114T/A POLYMORPHISM. Heart. 2012; 98(Suppl 2): E187.2–E187.
- Moher D, Liberati A, Tetzlaff J, et al. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Medicine. 2009; 6(7): e1000097.